Search hospitals > Texas > San Antonio
University of Texas Health Science Center at San Antonio
Claim this profileSan Antonio, Texas 78229
Global Leader in Uterine Tumors
Global Leader in Lymphoma
Conducts research for T-Lymphoblastic Leukemia/Lymphoma
Conducts research for Brain Tumor
Conducts research for Skin Cancer
1130 reported clinical trials
79 medical researchers
Summary
University of Texas Health Science Center at San Antonio is a medical facility located in San Antonio, Texas. This center is recognized for care of Uterine Tumors, Lymphoma, T-Lymphoblastic Leukemia/Lymphoma, Brain Tumor, Skin Cancer and other specialties. University of Texas Health Science Center at San Antonio is involved with conducting 1,130 clinical trials across 1,243 conditions. There are 79 research doctors associated with this hospital, such as Anne-Marie R. Langevin, John Browning, Virginia G. Kaklamani, and Michael A. Liss.Area of expertise
1Uterine Tumors
Global LeaderStage IV
Stage I
Stage III
2Lymphoma
Global LeaderStage II
Stage IV
Stage I
Top PIs
Anne-Marie R. LangevinUniversity of Texas Health Science Center at San Antonio7 years of reported clinical research
Expert in Uterine Tumors
Expert in Lymphoma
66 reported clinical trials
116 drugs studied
John BrowningTexas Dermatology and Laser Specialists1 year of reported clinical research
Studies Atopic Dermatitis
Studies Vasculopathic Skin Disease
15 reported clinical trials
20 drugs studied
Virginia G. KaklamaniUniversity of Texas Health Science Center at San Antonio8 years of reported clinical research
Expert in Breast Cancer
Studies Breast cancer
14 reported clinical trials
47 drugs studied
Michael A. LissUniversity of Texas Health Science Center at San Antonio4 years of reported clinical research
Studies Prostate Cancer
Studies Bladder Cancer
13 reported clinical trials
31 drugs studied
Clinical Trials running at University of Texas Health Science Center at San Antonio
Lung Cancer
Skin Cancer
Brain Tumor
Prostate Cancer
Breast Cancer
Uterine Tumors
Testicular cancer
Bladder Cancer
Type 2 Diabetes
Cancer
Thoracotomy vs Thoracoscopy
for Metastatic Osteosarcoma
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastases). Open thoracic surgery is a type of surgery done through a single larger incision (like a large cut) that goes between the ribs, opens up the chest, and removes the cancer. Thoracoscopy is a type of chest surgery where the doctor makes several small incisions and uses a small camera to help with removing the cancer. This trial is being done evaluate the two different surgery methods for patients with osteosarcoma that has spread to the lung to find out which is better.
Recruiting2 awards Phase 37 criteria
Radiation Therapy
for Brain Metastasis
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting2 awards Phase 312 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University of Texas Health Science Center at San Antonio?
Where is University of Texas Health Science Center at San Antonio located?
Who should I call to ask about financial aid or insurance network?
What insurance does University of Texas Health Science Center at San Antonio accept?
What awards or recognition has University of Texas Health Science Center at San Antonio received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.